Next Article in Journal
Cellular Localization and Trafficking of the Human ABCG1 Transporter
Previous Article in Journal
Mammalian Non-CpG Methylation: Stem Cells and Beyond
Previous Article in Special Issue
A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain
Article Menu

Export Article

Open AccessReview
Biology 2014, 3(4), 752-780; doi:10.3390/biology3040752

High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics

Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA
Author to whom correspondence should be addressed.
Received: 8 September 2014 / Revised: 28 October 2014 / Accepted: 30 October 2014 / Published: 14 November 2014
(This article belongs to the Special Issue Screening for Biologically Active Compounds)
View Full-Text   |   Download PDF [807 KB, uploaded 14 November 2014]   |  


Centers for the screening of biologically active compounds and genomic libraries are becoming common in the academic setting and have enabled researchers devoted to developing strategies for the treatment of diseases or interested in studying a biological phenomenon to have unprecedented access to libraries that, until few years ago, were accessible only by pharmaceutical companies. As a result, new drugs and genetic targets have now been identified for the treatment of Duchenne muscular dystrophy (DMD), the most prominent of the neuromuscular disorders affecting children. Although the work is still at an early stage, the results obtained to date are encouraging and demonstrate the importance that these centers may have in advancing therapeutic strategies for DMD as well as other diseases. This review will provide a summary of the status and progress made toward the development of a cure for this disorder and implementing high-throughput screening (HTS) technologies as the main source of discovery. As more academic institutions are gaining access to HTS as a valuable discovery tool, the identification of new biologically active molecules is likely to grow larger. In addition, the presence in the academic setting of experts in different aspects of the disease will offer the opportunity to develop novel assays capable of identifying new targets to be pursued as potential therapeutic options. These assays will represent an excellent source to be used by pharmaceutical companies for the screening of larger libraries providing the opportunity to establish strong collaborations between the private and academic sectors and maximizing the chances of bringing into the clinic new drugs for the treatment of DMD. View Full-Text
Keywords: dystrophin; utrophin; DMD; mdx; AONs; stop codon read-through; siRNA; RTC; Galgt2; HTS dystrophin; utrophin; DMD; mdx; AONs; stop codon read-through; siRNA; RTC; Galgt2; HTS

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gintjee, T.J.; Magh, A.S.; Bertoni, C. High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics. Biology 2014, 3, 752-780.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top